A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility

[1]  H. Lenz,et al.  The Molecular Taxonomy of Colorectal Cancer: What’s New? , 2015, Current Colorectal Cancer Reports.

[2]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[3]  M. Steinmetz,et al.  A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs , 2014, Proceedings of the National Academy of Sciences.

[4]  S. Friend,et al.  Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes. , 2014 .

[5]  R. Labianca,et al.  Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. , 2014 .

[6]  Hans Clevers,et al.  Intestinal crypt homeostasis revealed at single stem cell level by in vivo live-imaging , 2014, Nature.

[7]  Andreas Schlicker,et al.  Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition , 2013, International journal of cancer.

[8]  S. Rodenhuis,et al.  Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy , 2014, Breast Cancer Research.

[9]  C. Hashizume,et al.  Down-modulation of nucleoporin RanBP2/Nup358 impaired chromosomal alignment and induced mitotic catastrophe , 2013, Cell Death and Disease.

[10]  R. Bernards,et al.  TGF-β: An emerging player in drug resistance , 2013, Cell cycle.

[11]  J. Peeters,et al.  Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy , 2013, Breast Cancer Research and Treatment.

[12]  Lei Wang,et al.  The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis , 2013, PloS one.

[13]  R. Medema,et al.  Intravital FRET Imaging of Tumor Cell Viability and Mitosis during Chemotherapy , 2013, PloS one.

[14]  Jacco van Rheenen,et al.  Surgical implantation of an abdominal imaging window for intravital microscopy , 2013, Nature Protocols.

[15]  R. Bernards,et al.  MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling , 2012, Cell.

[16]  Jacco van Rheenen,et al.  Intravital Microscopy Through an Abdominal Imaging Window Reveals a Pre-Micrometastasis Stage During Liver Metastasis , 2012, Science Translational Medicine.

[17]  G. Capellá,et al.  Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype , 2012, Molecular carcinogenesis.

[18]  R. Weigert,et al.  Intravital microscopy , 2012, Bioarchitecture.

[19]  Philippe Dessen,et al.  Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer , 2012, Clinical Cancer Research.

[20]  Victor Moreno,et al.  A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction , 2012, Gut.

[21]  Julian Downward,et al.  Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies , 2012, Cell Research.

[22]  Sabine Tejpar,et al.  Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[24]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[25]  C. Bokemeyer,et al.  Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  R. Labianca,et al.  DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. , 2011, Journal of the National Cancer Institute.

[27]  E. Van Cutsem,et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Jorissen,et al.  Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation , 2011, International journal of cancer.

[29]  George A Calin,et al.  Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing , 2011, Proceedings of the National Academy of Sciences.

[30]  R. Medema,et al.  Cyclin G-associated kinase promotes microtubule outgrowth from chromosomes during spindle assembly , 2010, Chromosoma.

[31]  E. U. Cidon,et al.  Clinical Medicine Insights: Oncology the Challenge of Metastatic Colorectal Cancer Background , 2022 .

[32]  J. Barrett,et al.  KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  I. Nagtegaal,et al.  BRAF mutation in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[34]  R. Medema,et al.  RAMA1 is a novel kinetochore protein involved in kinetochore-microtubule attachment , 2009, Journal of Cell Science.

[35]  L. Pollak.  Moyamoya disease and moyamoya syndrome. , 2009, The New England journal of medicine.

[36]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[37]  P. Clarke,et al.  Spatial and temporal coordination of mitosis by Ran GTPase , 2008, Nature Reviews Molecular Cell Biology.

[38]  P. Lavia,et al.  Localized RanGTP accumulation promotes microtubule nucleation at kinetochores in somatic mammalian cells. , 2008, Molecular biology of the cell.

[39]  G. Mills,et al.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.

[40]  R. Bernards,et al.  Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence , 2006, Nature Cell Biology.

[41]  René Bernards,et al.  An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors , 2006, Nature chemical biology.

[42]  T. Karpova,et al.  Crm1 is a mitotic effector of Ran-GTP in somatic cells , 2005, Nature Cell Biology.

[43]  P. Clarke.  The Crm de la crème of mitosis , 2005, Nature Cell Biology.

[44]  M. Dasso,et al.  The RanGAP1-RanBP2 Complex Is Essential for Microtubule-Kinetochore Interactions In Vivo , 2004, Current Biology.

[45]  J. B. Rattner,et al.  Nup358 integrates nuclear envelope breakdown with kinetochore assembly , 2003, The Journal of cell biology.

[46]  M. Dasso,et al.  The Ran GTPase regulates kinetochore function. , 2003, Developmental cell.

[47]  J. McNally,et al.  SUMO-1 targets RanGAP1 to kinetochores and mitotic spindles , 2002, The Journal of cell biology.

[48]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[49]  T. Kanda,et al.  Histone–GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells , 1998, Current Biology.

[50]  N. Gebbia,et al.  Single agent vinorelbine in the treatment of unresectable lung metastases from colorectal cancer. , 1996, Oncology reports.

[51]  F. Caponigro,et al.  A phase-ii trial of 5-Fluorouracil, folinic Acid, vinorelbine in pretreated patients with metastic colorectal-cancer. , 1995, Oncology reports.

[52]  G. Giaccone,et al.  Complete remission of metastatic colorectal cancer: a pitfall in a multidrug resistance reversal trial , 1994, The Lancet.